Literature DB >> 15451791

Genetically determined resistance to collagenase action augments interstitial collagen accumulation in atherosclerotic plaques.

Yoshihiro Fukumoto1, Jun-o Deguchi, Peter Libby, Elena Rabkin-Aikawa, Yasuhiko Sakata, Michael T Chin, Christopher C Hill, Patrick R Lawler, Nerea Varo, Frederick J Schoen, Stephen M Krane, Masanori Aikawa.   

Abstract

BACKGROUND: We hypothesized that collagenolytic activity produced by activated macrophages contributes to collagen loss and the subsequent instability of atheromatous lesions, a common trigger of acute coronary syndromes. However, no direct in vivo evidence links collagenases with the regulation of collagen content in atherosclerotic plaques. METHODS AND
RESULTS: To test the hypothesis that collagenases influence the structure of atheromata, we examined collagen accumulation in atherosclerotic lesions of apolipoprotein E-deficient mice (apoE-/-) that express collagenase-resistant collagen-I (ColR/R/apoE-/-, n=12) or wild-type collagen-expressing mice (Col+/+/apoE-/-, n=12). Aortic atheromata of both groups had similar sizes and numbers of macrophages, a major source of collagenases. However, aortic intimas from ColR/R/apoE-/- mice contained fewer smooth muscle cells, a source of collagen, probably because of decreased migration or proliferation or increased cell death. Despite reduced numbers of smooth muscle cells, atheromata of ColR/R/apoE-/- mice contained significantly more intimal collagen than did those of Col+/+/apoE-/- mice.
CONCLUSIONS: These results establish that collagenase action regulates plaque collagen turnover and smooth muscle cell accumulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15451791     DOI: 10.1161/01.CIR.0000143174.41810.10

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  27 in total

Review 1.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

2.  Characterization of fracture behavior of human atherosclerotic fibrous caps using a miniature single edge notched tensile test.

Authors:  Lindsey A Davis; Samantha E Stewart; Christopher G Carsten; Bruce A Snyder; Michael A Sutton; Susan M Lessner
Journal:  Acta Biomater       Date:  2016-07-16       Impact factor: 8.947

Review 3.  Expanding role of delta-like 4 mediated notch signaling in cardiovascular and metabolic diseases.

Authors:  Daiju Fukuda; Masanori Aikawa
Journal:  Circ J       Date:  2013-09-12       Impact factor: 2.993

Review 4.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

5.  Collagenases and cracks in the plaque.

Authors:  Peter Libby
Journal:  J Clin Invest       Date:  2013-08-01       Impact factor: 14.808

Review 6.  Inflammation in atherosclerosis.

Authors:  Peter Libby
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09       Impact factor: 8.311

Review 7.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

Review 8.  Innate and adaptive immunity in atherosclerosis.

Authors:  René R S Packard; Andrew H Lichtman; Peter Libby
Journal:  Semin Immunopathol       Date:  2009-05-16       Impact factor: 9.623

9.  Myeloid-related protein-8/14 is critical for the biological response to vascular injury.

Authors:  Kevin Croce; Huiyun Gao; Yunmei Wang; Toshifumi Mooroka; Masashi Sakuma; Can Shi; Galina K Sukhova; René R S Packard; Nancy Hogg; Peter Libby; Daniel I Simon
Journal:  Circulation       Date:  2009-07-20       Impact factor: 29.690

10.  Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis.

Authors:  Peter Libby
Journal:  J Lipid Res       Date:  2008-12-18       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.